Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 7/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542061 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL13049236 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL1371518 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL14031258 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL13029576 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL6272209 | 0.86 | CYP2D6 (0.56) | MAPTCYP2D6THRBHSD17B10CA2 | |
| SCHEMBL14019274 | 0.86 | CYP2D6 (0.56) | MAPTCYP2D6THRBHSD17B10CA2 | |
| SCHEMBL5570985 | 0.86 | CYP2D6 (0.56) | MAPTCYP2D6THRBHSD17B10CA2 | |
| SCHEMBL17969688 | 0.86 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL17230115 | 0.84 | POLB (0.54) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632753-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2011-11-24 | — | — | US | disclosed |
| US-20050250700-A1 | KDR and VEGF/KDR binding peptides | BRACCO INTERNATIONAL B.V. (NL) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | LMNA 1815/4885KMT2A 2522/4885POLB 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.